AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions

Amedeo Lonardo, Fabio Nascimbeni, Giovanni Targher, Mauro Bernardi, Ferruccio Bonino, Elisabetta Bugianesi, Alessandro Casini, Amalia Gastaldelli, Giulio Marchesini, Fabio Marra, Luca Miele, Filomena Morisco, Salvatore Petta, Fabio Piscaglia, Gianluca Svegliati-Baroni, Luca Valenti, Stefano Bellentani

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic “hits”. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.

Original languageEnglish
Pages (from-to)471-483
Number of pages13
JournalDigestive and Liver Disease
Volume49
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Liver Neoplasms
Fibrosis
Biomarkers
Liver
Metabolic Diseases
Fatty Liver
Cardiomyopathies
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Direction compound
Non-alcoholic Fatty Liver Disease
Life Style
Cardiac Arrhythmias
Epidemiology
Cardiovascular Diseases
Pharmacology
Inflammation
Biopsy
Gastrointestinal Microbiome
Genetic Background

Keywords

  • Diagnosis
  • Epidemiology
  • Genetics
  • Management
  • Natural history
  • Physiopathology

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

AISF position paper on nonalcoholic fatty liver disease (NAFLD) : Updates and future directions. / Lonardo, Amedeo; Nascimbeni, Fabio; Targher, Giovanni; Bernardi, Mauro; Bonino, Ferruccio; Bugianesi, Elisabetta; Casini, Alessandro; Gastaldelli, Amalia; Marchesini, Giulio; Marra, Fabio; Miele, Luca; Morisco, Filomena; Petta, Salvatore; Piscaglia, Fabio; Svegliati-Baroni, Gianluca; Valenti, Luca; Bellentani, Stefano.

In: Digestive and Liver Disease, Vol. 49, No. 5, 01.05.2017, p. 471-483.

Research output: Contribution to journalArticle

Lonardo, A, Nascimbeni, F, Targher, G, Bernardi, M, Bonino, F, Bugianesi, E, Casini, A, Gastaldelli, A, Marchesini, G, Marra, F, Miele, L, Morisco, F, Petta, S, Piscaglia, F, Svegliati-Baroni, G, Valenti, L & Bellentani, S 2017, 'AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions', Digestive and Liver Disease, vol. 49, no. 5, pp. 471-483. https://doi.org/10.1016/j.dld.2017.01.147
Lonardo, Amedeo ; Nascimbeni, Fabio ; Targher, Giovanni ; Bernardi, Mauro ; Bonino, Ferruccio ; Bugianesi, Elisabetta ; Casini, Alessandro ; Gastaldelli, Amalia ; Marchesini, Giulio ; Marra, Fabio ; Miele, Luca ; Morisco, Filomena ; Petta, Salvatore ; Piscaglia, Fabio ; Svegliati-Baroni, Gianluca ; Valenti, Luca ; Bellentani, Stefano. / AISF position paper on nonalcoholic fatty liver disease (NAFLD) : Updates and future directions. In: Digestive and Liver Disease. 2017 ; Vol. 49, No. 5. pp. 471-483.
@article{aad85a8b0bee4b498e85c031bb12824f,
title = "AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions",
abstract = "This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic “hits”. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.",
keywords = "Diagnosis, Epidemiology, Genetics, Management, Natural history, Physiopathology",
author = "Amedeo Lonardo and Fabio Nascimbeni and Giovanni Targher and Mauro Bernardi and Ferruccio Bonino and Elisabetta Bugianesi and Alessandro Casini and Amalia Gastaldelli and Giulio Marchesini and Fabio Marra and Luca Miele and Filomena Morisco and Salvatore Petta and Fabio Piscaglia and Gianluca Svegliati-Baroni and Luca Valenti and Stefano Bellentani",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.dld.2017.01.147",
language = "English",
volume = "49",
pages = "471--483",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - AISF position paper on nonalcoholic fatty liver disease (NAFLD)

T2 - Updates and future directions

AU - Lonardo, Amedeo

AU - Nascimbeni, Fabio

AU - Targher, Giovanni

AU - Bernardi, Mauro

AU - Bonino, Ferruccio

AU - Bugianesi, Elisabetta

AU - Casini, Alessandro

AU - Gastaldelli, Amalia

AU - Marchesini, Giulio

AU - Marra, Fabio

AU - Miele, Luca

AU - Morisco, Filomena

AU - Petta, Salvatore

AU - Piscaglia, Fabio

AU - Svegliati-Baroni, Gianluca

AU - Valenti, Luca

AU - Bellentani, Stefano

PY - 2017/5/1

Y1 - 2017/5/1

N2 - This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic “hits”. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.

AB - This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic “hits”. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.

KW - Diagnosis

KW - Epidemiology

KW - Genetics

KW - Management

KW - Natural history

KW - Physiopathology

UR - http://www.scopus.com/inward/record.url?scp=85013040868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013040868&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2017.01.147

DO - 10.1016/j.dld.2017.01.147

M3 - Article

AN - SCOPUS:85013040868

VL - 49

SP - 471

EP - 483

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 5

ER -